Clinical trial
Evaluation of the Safety and Effectiveness of Switching From Originator (Humira®) to Biosimilar (Imraldi®) Adalimumab in Flanders (SafE-OrBi)
NCT04045782 is registered in ClinicalTrials.gov with Pieter Dewint, MD PhD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of the Safety and Effectiveness of Switching From Originator (Humira®) to Biosimilar (Imraldi®) Adalimumab in Flanders (SafE-OrBi)
- Lead sponsor
- Pieter Dewint, MD PhD
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- August 19, 2019
- Completion date
- January 29, 2021
- Enrollment
- 130 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.